- Supported exchanges /
- F /
- 3DMA.F
KINTARA THER. NEW DL-001 (3DMA F) stock market data APIs
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
KINTARA THER. NEW DL-001 Financial Data Overview
| 6.951 | |
| 6.951 | |
| - | |
| 6.951 | |
| 6.951 | |
| 2.45-16.1 | |
| 11 054 K | |
| 55 661 K | |
| 0 | |
| 0.812 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
KINTARA THER. NEW DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -8 396 000
- Earnings Per Share -10.29
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get KINTARA THER. NEW DL-001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get KINTARA THER. NEW DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
